1. Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice
  2. Superiority of Fesoterodine 8 mg Versus Fesoterodine 4 mg in Reducing Urgency Urinary Incontinence Episodes in Subjects with Overactive Bladder: Results of the Randomized, Double-Blind, Placebo-Controlled EIGHT Trial
  3. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence
  4. Do Patient Characteristics Predict Responsiveness to Treatment of Overactive Bladder With Antimuscarinic Agents?
  5. Use of desipramine for the treatment of overactive bladder refractory to antimuscarinic therapy
  6. Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?
  7. Evaluation and management of patients with nocturia
  8. Design, Synthesis and Evaluation of Conformationally Restricted Acetanilides as Potent and Selective ?3 Adrenergic Receptor Agonists for the Treatment of Overactive Bladder
  9. What is the role for biomarkers for lower urinary tract disorders? ICI-RS 2013
  10. Overactive bladder symptom score to evaluate efficacy of solifenacin for the treatment of overactive bladder symptoms
  11. Onset of action of the ?3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
  12. Rationale for the Use of Anticholinergic Agents in Overactive Bladder With Regard to Central Nervous System and Cardiovascular System Side Effects
  13. Direct and indirect cost of urge urinary incontinence with and without pharmacotherapy
  14. Effect of Holmium Laser Enucleation of Prostate on Overactive Bladder Symptoms and Urodynamic Parameters: A Prospective Study
  15. Urgency and pain in patients with overactive bladder and bladder pain syndrome. What are the differences?
  16. A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder
  17. Does concomitant diabetes affect treatment responses in overactive bladder patients?
  18. Defining response and non-response to treatment in patients with overactive bladder: a systematic review
  19. Cognitive adverse effects of anticholinergic medication for overactive bladder in PD/DLB
  20. Overactive bladder and pontine reticular formation
  21. Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison
  22. An Updated Systematic Review and Statistical Comparison of Standardised Mean Outcomes for the Use of Botulinum Toxin in the Management of Lower Urinary Tract Disorders
  23. Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder
  24. A randomised, double-blind, parallel design, multi-institutional, non-inferiority phase IV trial of imidafenacin versus fesoterodine for overactive bladder
  25. Sacral neuromodulation for refractory overactive bladder, interstitial cystitis, and painful bladder syndrome
  26. Obese children at higher risk for having overactive bladder symptoms: A community-based study
  27. Percutaneous tibial nerve stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review
  28. Long term follow up of sacral neuromodulation for lower urinary tract dysfunction.
  29. Efficacy and safety of low-dose anticholinergics to treat men with lower urinary tract symptoms with overactive bladder: a retrospective study based on real life practice
  30. Randomized controlled trial to compare the safety and efficacy of tamsulosin, solifenacin, and combination of both in treatment of double-j stent-related lower urinary symptoms
  31. Evaluation of fesoterodine fumarate for the treatment of an overactive bladder
  32. Use of herbal supplements for overactive bladder
  33. Electrical and Mechanical Office-based Neuromodulation
  34. Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis
  35. Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain
  36. Stem Cell Therapy in Bladder Dysfunction: Where Are We? And Where Do We Have to Go?
  37. Does concomitant diabetes affect treatment responses in overactive bladder patients?
  38. Comparison of Motor and Sensory Response of InterStim® for Overactive Bladder Syndrome
  39. Pharmacokinetics of Mirabegron, a ?3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy Japanese Male Subjects: Results from Single- and Multiple-Dose Studies
  40. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review
  41. Urologists' referral attitude for sacral neuromodulation for treating refractory idiopathic overactive bladder syndrome: Discrete choice experiment
  42. Validation of the Bladder Control Self-Assessment Questionnaire (B-SAQ) in men
  43. Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability
  44. Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: A randomized, double-blind, placebo-controlled study
  45. How to define a refractory idiopathic overactive bladder?
  46. Defining Response and Non-Response to Treatment in Patients With Overactive Bladder: A Systematic Review
  47. Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: Results of a real-life clinical study
  48. Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents
  49. Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy
  50. Overactive bladder in diabetes mellitus patients: a questionnaire-based observational investigation
  51. Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly
  52. Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study
  53. Long-Term Patterns of Use and Treatment Failure With Anticholinergic Agents for Overactive Bladder
  54. Mirabegron for Overactive Bladder: A Novel, First-in-Class ?3- Agonist Therapy
  55. Comorbidities and personal burden of urgency urinary incontinence: a systematic review
  56. Efficacy and safety of propiverine and terazosine combination for one year in male patients with luts and detrusor overactivity
  57. The use of botulinum toxin for the treatment of urologic pain
  58. Tolterodine activates the prefrontal cortex during bladder filling in OAB patients: A real-time NIRS-urodynamics study
  59. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial
  60. Global Prevalence and Economic Burden of Urgency Urinary Incontinence: A Systematic Review
  61. A Randomised, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of the EP-1 Receptor Antagonist, ONO-8539, in Patients with Non-Neurogenic Overactive Bladder Syndrome
  62. Nocturia Quality-of-Life questionnaire is a useful tool to predict nocturia and a risk of falling in Japanese outpatients: A cross-sectional survey
  63. Screening test for overactive bladder in a newly developed comprehensive geriatric assessment initiative
  64. The Impact of OAB on Physical Activity in the United States: Results from OAB-POLL
  65. Botulinum Toxin-A Injections for Idiopathic Overactive Bladder: A Systematic Review and Meta-Analysis
  66. Clinical Efficacy and Safety of Imidafenacin as Add-on Treatment for Persistent Overactive Bladder Symptoms Despite ?-Blocker Treatment in Patients With BPH: The ADDITION STUDY
  67. Mirabegron for Male Lower Urinary Tract Symptoms
  68. The concept of peripheral modulation of bladder sensation
  69. What do we know and not know about mirabegron, a novel ?3 agonist, in the treatment of overactive bladder?
  70. Overactive Bladder in Elderly Men: Epidemiology, Evaluation, Clinical Effects, and Management
  71. Update on Behavioral and Physical Therapies for Incontinence and Overactive Bladder: The Role of Pelvic Floor Muscle Training
  72. Examining mechanisms of brain control of bladder function with resting state functional connectivity MRI
  73. Urodynamics: Examining the Current Role of UDS Testing. What is the Role of Urodynamic Testing in Light of Recent AUA Urodynamics and Overactive Bladder Guidelines and the VALUE Study?
  74. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity
  75. Tolterodine for the treatment of urge urinary incontinence
  76. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials
  77. Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder
  78. Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom
  79. New therapies in the treatment of overactive bladder
  80. Imidafenacin, an Antimuscarinic Agent, Improves Nocturia and Reduces Nocturnal Urine Volume
  81. Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients
  82. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy
  83. Increased bladder wall thickness in diabetic and nondiabetic women with overactive bladder
  84. The association between the self-perception period of overactive bladder symptoms and overactive bladder symptom scores in a non-treated population and related sociodemographic and lifestyle factors
  85. Effect of low-dose triple therapy using gabapentin, amitriptyline, and a nonsteroidal anti-inflammatory drug for overactive bladder symptoms in patients with bladder pain syndrome
  86. Treatment Status and Progression or Regression of Lower Urinary Tract Symptoms among Adults in a General Population Sample
  87. Male overactive bladder: pharmacotherapy for the male
  88. Voiding diary might serve as a useful tool to understand differences between bladder pain syndrome/interstitial cystitis and overactive bladder
  89. Evidence available on the use of the selective ?3-adrenoceptor agonist mirabegron for the treatment of overactive bladder
  90. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder
  91. Neuromodulation for overactive bladder
  92. Mirabegron: A Review of Its Use in Patients with Overactive Bladder Syndrome
  93. Anticholinergic therapy for overactive bladder: A nicotinic modality?
  94. Imidafenacin on bladder and cognitive function in neurologic OAB patients
  95. Understanding Clinic Options for Overactive Bladder
  96. Cardiovascular effects of antimuscarinic agents in overactive bladder
  97. Reliability and validity of the overactive bladder symptom score in Hong Kong Chinese
  98. Long-Term Experience With Sodium Chondroitin Sulfate in Patients With Painful Bladder Syndrome
  99. Neurotrophins in bladder function: What do we know and where do we go from here?
  100. Efficacy and Safety of Botulinum Toxin A Intradetrusor Injections in Adults with Neurogenic Detrusor Overactivity/Neurogenic Overactive Bladder: A Systematic Review
  101. A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the ?3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder
  102. The Prevalence and Risk Factors of OAB in Middle-Aged and Old People in China
  103. Efficacy and safety of repeated dosing of netupitant, a neurokinin-1 receptor antagonist, in treating overactive bladder
  104. Validation of the Spanish Version of the Questionnaire «Benefit, Satisfaction and Willingness to Continue the Treatment» in Patients with Overactive Bladder
  105. Ramelteon combined with an alpha1-blocker might decreases nocturia in men with benign prostatic hyperplasia
  106. Psychometric Performance of the Incontinence Quality-of-Life Questionnaire Among Patients With Overactive Bladder and Urinary Incontinence
  107. The effect of mirabegron, a potent and selective ?3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol
  108. Mirabegron: ?3-Adrenergic Receptor Agonist for the Treatment of Overactive Bladder (July/August)
  109. Urinary Disorders and Female Sexual Function
  110. Reproducibility study of Overactive Bladder Symptom Score questionnaire and its response to treatment (RESORT) in Korean population with overactive bladder symptoms
  111. Overactive bladder mediated by accelerated Ca2+ influx mode of Na+/Ca2+ exchanger in smooth muscle
  112. Intake of Caffeinated, Carbonated, or Citrus Beverage Types and Development of Lower Urinary Tract Symptoms in Men and Women
  113. ?3-Receptor Agonists for Overactive Bladder-New Frontier or More of the Same?
  114. Neurogenic bladder and disc disease:A brief review
  115. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
  116. The other bladder syndrome: underactive bladder
  117. The role of phosphodiesterases in bladder pathophysiology
  118. The use of botulinum toxin for the treatment of overactive bladder syndrome
  119. Efficacy and tolerability of combined medication of two different antimuscarinics for treatment of adults with idiopathic overactive bladder in whom a single agent antimuscarinic therapy failed
  120. Urinary nerve growth factor: a biomarker of detrusor overactivity? A systematic review
  121. Finger taps and constipation are closely related to symptoms of overactive bladder in male patients with Parkinson's disease
  122. Development and validation of the Chinese Overactive Bladder Symptom Score for assessing overactive bladder syndrome in a RESORT study
  123. Impact of overactive bladder treatment on the quality of life of patients over 60 with associated pathologies
  124. Understanding the effects on HR-QoL of treatment for overactive bladder: a detailed analysis of EQ-5D clinical trial data for mirabegron
  125. Correlation Between Overactive Bladder Symptoms and Quality of Life in Japanese Male Patients: Focus on Nocturia
  126. New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
  127. Overactive bladder symptom severity is associated with falls in community-dwelling adults: LOHAS study
  128. Role of Cytochrome P450 Isoenzymes 3A and 2D6 in the In Vivo Metabolism of Mirabegron, a ?3-Adrenoceptor Agonist
  129. Botulinum toxin treatment for bladder dysfunction
  130. Short-term Effects of a Systematized Bladder Training Program for Idiopathic Overactive Bladder: A Prospective Study
  131. OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial
  132. Optimizing the Duration of Assessment of Stage-1 Sacral Neuromodulation in Nonobstructive Chronic Urinary Retention
  133. Onabotulinum toxin a (botox®) in the treatment of neurogenic bladder overactivity
  134. The assessment of a novel electrical stimulation waveform recently introduced for the treatment of overactive bladder
  135. Current pharmacotherapy of nocturia
  136. Intestinal Absorption Mechanism of Mirabegron, a Potent and Selective ?3-Adrenoceptor Agonist: Involvement of Human Efflux and/or Influx Transport Systems
  137. The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option
  138. Solifenacin Succinate versus Percutaneous Tibial Nerve Stimulation in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Crossover Study
  139. Influence of type of nocturia and lower urinary tract symptoms on therapeutic outcome in women treated with desmopressin
  140. Actual treatment of overactive bladder and urge urinary incontinence
  141. Mapping EQ-5D Utility Scores from the Incontinence Quality of Life Questionnaire among Patients with Neurogenic and Idiopathic Overactive Bladder
  142. Validation study of the Self-Assessment Goal Achievement (SAGA) questionnaire for lower urinary tract symptoms
  143. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults
  144. Neurology and the bladder: how to assess and manage neurogenic bladder dysfunction. With particular references to neural control of micturition
  145. Clinical outcomes of sacral neuromodulation in patients with neurologic conditions
  146. Increasing Patient Preparedness for Sacral Neuromodulation Improves Patient-reported Outcomes Despite Leaving Objective Measures of Success Unchanged
  147. Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox® ) or abobotulinumtoxinA (Dysport® ) make a difference?
  148. Factors Associated With a Better Therapeutic Effect of Solifenacin in Patients With Overactive Bladder Syndrome
  149. Involvement of Connexins 43 and 45 in Functional Mechanism of Human Detrusor Overactivity in Neurogenic Bladder
  150. Practical Use of the New American Urological Association Adult Urodynamics Guidelines
  151. Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder
  152. Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: Open-label extension of the SOFIA trial
  153. A phase II dose-ranging study of mirabegron in patients with overactive bladder
  154. Downregulation of NGF Expression in the Bladder by Antisense Oligoucleotides as New Treatment for Overactive Bladder
  155. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?
  156. Objective Evaluation of Overactive Bladder: Which Surveys Should I Use?
  157. A proof-of-concept study: Mirabegron, a new therapy for overactive bladder
  158. Clinical value of a patient-reported goal-attainment measure: The global development of Self-Assessment Goal Achievement (SAGA) questionnaire for patients with lower urinary tract symptoms
  159. The management of overactive bladder refractory to medical therapy
  160. Overactive bladder symptoms, stress urinary incontinence and associated bother in women aged 40 and above; a Belgian epidemiological survey
  161. Systematic review of the relationship between bladder and bowel function: implications for patient management
  162. The medical management of refractory Overactive Bladder
  163. Correlation Between Age and Overactive Bladder Symptoms in Young Women in Brazil
  164. Management of refractory overactive bladder
  165. Defining and managing overactive bladder: disagreement among the experts
  166. Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder
  167. Long-term safety, efficacy, and tolerability of imidafenacin in the treatment of overactive bladder: a review of the Japanese literature
  168. New Perspectives of Treatment With Fesoterodine Fumarate in Patients With Overactive Bladder
  169. Flexible-Dose Fesoterodine in Elderly Adults with Overactive Bladder: Results of the Randomized, Double-Blind, Placebo-Controlled Study of Fesoterodine in an Aging Population Trial
  170. Randomised, Multicentre, Placebo-controlled, Double-blind Crossover Study Investigating the Effect of Solifenacin and Oxybutynin in Elderly People with Mild Cognitive Impairment: The SENIOR Study
  171. Experience with imidafenacin in the management of overactive bladder disorder
  172. Intravesical drug delivery for dysfunctional bladder
  173. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3 Randomized Placebo-Controlled Trial
  174. Biomarkers in overactive bladder
  175. Onabotulinumtoxin a for treating overactive/poor compliant bladders in children and adolescents with neurogenic bladder secondary to myelomeningocele
  176. Efficacy and Tolerability of Mirabegron, a ?(3)-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 Trial
  177. Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a ?(3)-Adrenoceptor Agonist, in Overactive Bladder
  178. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation
  179. Propiverine : A Review of its Use in the Treatment of Adults and Children with Overactive Bladder Associated with Idiopathic or Neurogenic Detrusor Overactivity, and in Men with Lower Urinary Tract Symptoms
  180. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE)
  181. Urinary neurotrophic factors in healthy individuals and patients with overactive bladder
  182. Safety and Tolerability of Solifenacin Add-on Therapy to ?-Blocker Treated Men With Residual Urgency and Frequency